Evidence map›Paper›PMID 40755380›Full record

ArticleFuture medicinal chemistry2025

Design, synthesis, anti-breast cancer and

Arun Kumar, Sounok Sengupta, Ashok Kumar Yadav, Raman Preet Singh, Tripti Sinha, Pratiti Bhattacharjee, Biswarup Basu, G Marriapan, Sanjib Bhattacharyya, Deepak Kumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arun KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, India.
Sounok SenguptaDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, India.
Ashok Kumar YadavUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Raman Preet SinghGovernment Polytechnic College, Patiala, India.
Tripti SinhaDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, India.
Pratiti BhattacharjeeDepartment of Neuroendocrinology & Experimental Hematology, Chittaranjan National Cancer Institute, Kolkata, India.
Biswarup BasuDepartment of Neuroendocrinology & Experimental Hematology, Chittaranjan National Cancer Institute, Kolkata, India.
G MarriapanDepartment of Pharmaceutical Chemistry, St Mary's College of Pharmacy, Secunderabad, India.
Sanjib BhattacharyyaDepartment of Neurosurgery, The University of Texas Health Science Center at Houston, TX, USA.
Deepak KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, India.ORCID 0000-0003-2241-0054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimCancer is an affliction on societies worldwide, chemotherapy, though effective, has its limitations, indicating the need for new therapeutic agents. Imidazole and indole are two important bioactive heterocycles important for developing newer anticancer molecules.We synthesized a series of substituted imidazole-linked indole derivatives and evaluated them for anticancer activity on MCF-7 cells. Further MATERIALS AND

methodsCompounds were synthesized by preparing substituted triphenyl imidazoles from benzaldehydes and were further linked to indoles using

resultsCompounds were confirmed by

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug DesignImidazolesIndolesApoptosisCell CycleCell ProliferationDensity Functional TheoryDrug Screening Assays, AntitumorFemaleHumansMCF-7 CellsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureAntineoplastic AgentsImidazolesIndolesanticancer activityapoptosisbreast cancercell cycle analysisDFT and QSARImidazole and indolemolecular docking and dynamic

Identifiers

PMID40755380
PMCPMC12506756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.